Business Wire | Oct 28, 2020 11:00AM EDT

EOLS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Evolus, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: December 15, 2020

Oct. 28, 2020

NEW YORK--(BUSINESS WIRE)--Oct. 28, 2020--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Evolus, Inc. ("Evolus" or "the Company") (NASDAQ: EOLS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Evolus securities between February 1, 2019 to July 6, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/eols.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements that: (1) the real source of botulinum toxin bacterial strain as well as the manufacturing processes used to develop Jeuveau(tm) originated with and were misappropriated from Medytox; (2) sufficient evidentiary support existed for the allegations that Evolus misappropriated certain trade secrets relating to the botulin toxin strain and the manufacturing processes for the development of Jeuveau(tm); (3) as a result, Evolus faced a real threat of regulatory and/or court action, prohibiting the import, marketing, and sale of Jeuveau(tm); (4) which in turn seriously threatened Evolus' ability to commercialize Jeuveau(tm) in the United States and generate revenue; and (5) any revenues generated from the sale of Jeuveau(tm) were based on Evolus' unlawful activities, including the misappropriation of trade secrets and secret manufacturing processes belonging to Allergan and Medytox.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/eols or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Evolus you have until December 15, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005017/en/

CONTACT: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | info@bgandg.com